Every Form 4 that MapLight Therapeutics, Inc. (MPLT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MPLT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MPLT filings page.
MapLight Therapeutics Chief Scientific Officer receives new equity awards. On February 5, 2026, Lillie James Woodruff was granted 7,730 restricted stock units of voting common stock and an option to purchase 31,395 shares at an exercise price of $15.7 per share.
The RSUs vest 25% on January 1, 2027, with the remainder vesting in equal quarterly installments, subject to continued service. The stock option vests 25% on February 5, 2027, with the balance vesting in equal monthly installments thereafter. Following the RSU grant, Woodruff beneficially owns 298,862 shares of voting common stock and 31,395 stock options, all held directly.
MapLight Therapeutics Chief Discovery Officer Anatol Kreitzer reported equity awards of 6,020 restricted stock units and 24,455 employee stock options dated February 5, 2026. The RSUs vest 25% on January 1, 2027, with the remaining 75% vesting in equal quarterly installments, subject to continued service.
The options have a $15.70 exercise price and begin vesting with 25% on February 5, 2027, then monthly vesting for the remaining shares. Following the RSU grant, Kreitzer directly holds 259,928 shares of voting common stock, and 24,455 options after the option grant.
MapLight Therapeutics, Inc. reported that its General Counsel, Kristopher Hanson, received new equity awards on February 5, 2026. He acquired 7,730 shares of voting common stock through a restricted stock unit grant at a stated price of $0, bringing his directly held total to 191,582 shares.
He was also granted an employee stock option for 31,395 shares at an exercise price of $15.7 per share. One quarter of the RSUs vest on January 1, 2027, and the remainder in equal quarterly installments, while one quarter of the option vests on February 5, 2027, with the balance vesting monthly thereafter, all contingent on continued service.
MapLight Therapeutics Chief Medical Officer Erin Pennock Foff reported new equity awards in the company’s voting common stock. She received 13,360 restricted stock units at a price of $0, which begin vesting on January 1, 2027 and then quarterly in equal installments, subject to continued service.
She was also granted an employee stock option for 54,240 shares at an exercise price of $15.7 per share. One quarter of these option shares vest on February 5, 2027, with the remainder vesting monthly thereafter, again contingent on ongoing service. Following these grants, she directly beneficially owns 403,835 shares of voting common stock and 54,240 options.
MapLight Therapeutics reported that Chief Executive Officer and director Christopher A. Kroeger received new equity awards. On February 5, 2026, he was granted 23,145 restricted stock units, each representing one share of voting common stock, at a price of $0. After this grant, he directly beneficially owned 1,649,751 shares of voting common stock.
On the same date, Kroeger also received an option to buy 93,955 shares of voting common stock at an exercise price of $15.70 per share, with vesting beginning in 2027. In addition, 101,190 shares of voting common stock are held indirectly through the C&M Kroeger Nominee Trust, where he and his spouse serve as co‑trustees with voting and dispositive power.
MapLight Therapeutics director Robert C. Malenka reported small open-market sales of voting common stock mainly to cover taxes on vested restricted stock units. On February 2, 2026, he sold 7,039 shares at a weighted average price of $18.02, and on February 3, 2026, he sold 1 share at $18.00.
After these sales, he beneficially owns 358,233 shares directly and 31,672 shares indirectly through the Robert C. Malenka Living Trust, where he has voting and dispositive power. The remaining securities he holds are still subject to a 180-day IPO lock-up following the final prospectus dated October 26, 2025.
MapLight Therapeutics director Robert C. Malenka reported selling voting common stock primarily to cover taxes on restricted stock units. On January 28–30, 2026, he sold several blocks of shares at weighted average prices between about $18 and $19 per share.
After these sales, he beneficially owns 365,273 shares directly and 31,672 shares indirectly through the Robert C. Malenka Living Trust, where he serves as sole trustee with voting and dispositive power. The retained shares remain subject to a 180‑day IPO lock-up following the October 26, 2025 final prospectus.
MapLight Therapeutics Chief Financial Officer reports routine tax-related share withholding. On January 27, 2026, 33,382 shares of voting common stock were withheld by the company at $17.98 per share to cover tax obligations tied to a restricted stock unit settlement.
After this transaction, the CFO beneficially owned 387,819 shares directly. The remaining securities are still subject to a lock-up agreement linked to MapLight’s initial public offering, restricting most transfers for 180 days after the final prospectus dated October 26, 2025.
MapLight Therapeutics Chief Scientific Officer Lillie James Woodruff reported a tax-withholding transaction in company stock. On January 27, 2026, 45,055 shares of Voting Common Stock were withheld at $17.98 per share to cover taxes from restricted stock unit settlement, a non-open-market event coded “F.”
After this withholding, Woodruff beneficially owned 291,132 shares directly. The remaining securities continue to be subject to an IPO lock-up agreement, under which Woodruff agreed, with certain exceptions, not to sell or transfer issuer securities for 180 days following the final IPO prospectus dated October 26, 2025.
MapLight Therapeutics Chief Discovery Officer Anatol Kreitzer reported a tax-related share withholding connected to restricted stock units. On January 27, 2026, 42,099 shares of Voting Common Stock were withheld at $17.98 per share to satisfy tax obligations.
After this withholding, Kreitzer directly beneficially owns 253,908 shares of MapLight Therapeutics stock. The remaining securities he holds are subject to a lock-up agreement tied to the company’s initial public offering, restricting most sales for 180 days after the October 26, 2025 final IPO prospectus.
MapLight Therapeutics officer Jonathan Gillis, who serves as CAAO and PAO, reported a tax-related share withholding on January 27, 2026. The transaction involved 22,050 shares of Voting Common Stock (code F) at $17.98 per share, used to satisfy tax withholding on restricted stock unit settlements.
Following this withholding, Gillis beneficially owned 248,503 shares directly. The remaining securities he holds are still subject to a lock-up agreement related to MapLight’s initial public offering, restricting most transfers for 180 days after the final prospectus dated October 26, 2025.
MapLight Therapeutics CEO Christopher A. Kroeger reported a tax-related share withholding tied to equity compensation. On January 27, 2026, 204,146 shares of MapLight voting common stock were withheld by the company at a price of $17.98 per share to satisfy tax obligations from restricted stock unit settlements.
Following this transaction, Kroeger held 1,626,606 shares of voting common stock directly. In addition, 101,190 shares were held indirectly through the C&M Kroeger Nominee Trust, where he and his spouse serve as co-trustees with voting and dispositive power. The retained securities remain subject to a lock-up agreement lasting 180 days after the October 26, 2025 final IPO prospectus, limiting sales or transfers except for certain permitted exceptions.
MapLight Therapeutics Chief Medical Officer Erin Pennock Foff reported a tax-related share withholding tied to restricted stock units. On January 27, 2026, 44,616 shares of MapLight voting common stock were withheld at $17.98 per share to cover tax obligations, leaving 390,475 shares beneficially owned directly. The remaining securities are still subject to a 180-day IPO lock-up following the final prospectus date of October 26, 2025, limiting sales or transfers during that period.
MapLight Therapeutics General Counsel Kristopher Hanson reported a tax-related share withholding tied to restricted stock units. On January 27, 2026, the issuer withheld 26,007 shares of Voting Common Stock at $17.98 per share to cover tax obligations from RSU settlement.
After this transaction, Hanson beneficially owned 183,852 shares directly. The remaining securities he holds are still subject to a 180-day IPO lock-up following the final prospectus dated October 26, 2025, limiting his ability to sell or transfer those shares during that period.